Established in 2008, Therapeutic Innovation Australia (TIA) is the lead agent for the National Collaborative Research Infrastructure Strategy (NCRIS) “Therapeutic Innovation Australia” project funded by the Australian Department of Education.
TIA supports national research infrastructure across four capabilities :
• Biologics & Vaccines
• Cell & Gene Therapies
• Small Molecule Therapeutics
• RNA Products
Strategic Plan
We have developed a Strategic Plan for the period 2023-2028 that outlines key strategic aims associated with support of a network of Australian translational research infrastructure.
Vision
For the Australian research community to have access to world class research infrastructure to enable efficient translation of therapeutics to improve human health.
Mission
TIA will enable and accelerate the translation of research discovery along the therapeutic development pipeline by investing in world class research infrastructure facilities so they are coordinated, comprehensive, accessible and responsive to the needs of the Australian translational research community.
TIA Board
TIA Ltd is a not-for-profit company limited by guarantee, and is governed by applicable legislation. TIA is overseen by an independent, skills-based Board that meets monthly, and a Governance, Audit and Risk Committee chaired by the Company Secretary that meets every two months. The Board members are knowledgable individuals with extensive experience in the public, private and not-for-profit sectors.
Mr Terry Slater AM
BSc, BEc, MPH, MAICD, FAIM
Chair
Prof Judith Whitworth AC
MBBS, MD, PhD, DSc (Melb),HonDSc (Glasgow), FRACP, FAICD, FTSE, FAHMS (hon), MD (hon), Syd, MD (hon) UNSW, D Lett (hon) CDU, LD (hon) Melb
Director
Mr Rob Anderson
FCA, FAICD
Company Secretary
Prof Ross McKinnon
B Pharm, B Sci (Hons), PhD, FFIP, FGLF, FAHMS, MAICD Director
Management
TIA’s management consists of a CEO and a Director of Programs, supported by a Scientific Advisor to the Board and a Board Secretary.
Dr Stuart Newman
PhD GAICD
Chief Executive Officer
Dr MJ Chua
PhD
Director of Programs
A/Prof Stella Clark AM
PhD, GAICD
Scientific Adviser to the Board
Lesley Bath
Melbourne Office Manager and Board Secretary
Engagement team
TIA provides support to the sector via a scientific engagement team. These experts in their field are tasked with helping to build and maintain the network of TIA capabilities, as well as provide promotion and referral to TIA facilities.
Mr Ben Hughes
Director of Strategic Development, Biologics and RNA Products
Dr John Parisot
PhD
Strategic Partnerships Advisor
Dr Heather Donaghy
PhD
Director of Strategic Development, Cell & Gene Therapies
Fanny Peters
Impact and Communications Manager
Equity
TIA Values Diversity and Equity
Life science and biomedical research enjoys a more favourable gender balance and diversity profile than many other sectors, but as roles become more senior this balance markedly shifts to favour men over women and marginalised groups.
As a source of funding for employment of biomedical research support and technical staff, TIA takes seriously its responsibility to contribute to an appropriate gender balance and a culture of inclusion at all levels of seniority across the sector.
TIA’s staff and Board abide by the following principles:
- We pledge to increase the visibility and contribution of women leaders, as well as those from under-represented communities or groups, in public and professional forums
- We will make our commitment known
- We will actively encourage diverse voices and will encourage others to take-up a Panel Pledge
- We will honour the Panel Pledge when invited to speak by raising the issue of diversity when the opportunity arises
This pledge is made with the endorsement of the Board and Staff of Therapeutic Innovation Australia Ltd
This pledge is adapted from material from the Champions of Change coalition website. TIA has provided staff with guidance on responding to requests to speak at public events to courteously ask questions on the diversity and gender balance of the panel or program.
Please contact us to discuss this pledge or other issues of equity and diversity relating to biomedical and life sciences research.
